Disclaimer

The trademark information displayed on this page is public information and is provided for informational purposes only. This information may be incomplete, inaccurate, or outdated, and IndiaFilings does not guarantee its accuracy. IndiaFilings is an independent platform and is not associated, affiliated, or connected with any trademark listed in this database. We do not represent or speak on behalf of any such trademark. If you are trying to contact a specific trademark, please use their official channels. IndiaFilings cannot assist with queries directed at other companies.

ACEPAR

Class 5Status: Accepted & Advertised
Application Number6865420
Trademark Status
Accepted & Advertised
Trademark Class5
Application Date2025-02-19
Proprietor NameDAKSH PHARMACEUTICALS PVT LTD
Appropriate OfficeDELHI
StateHARYANA
Trademark TypeWORD
User Details27/12/2006
Agent NameAMAN GUPTA[27904]
Agent AddressHouse No.99 DDA Market Hari Nager Ashram New Delhi 110014
Goods And Services Details[CLASS : 5] MEDICAL AND PHARMACEUTICALS PREPARATIONS.

Identical Trademarks

Similar trademarks found for this brand

2 found
BrandClassStatus
ACEPAR5Accepted & Advertised
ACEPAR5Accepted & Advertised
Showing up to 6 identical trademarksView more on LEDGERS→

Trademark Protection

Automate the monitoring of your trademark application and filing of response to Government Objection or Hearing.

₹9,899+ GST

What's included:

✓
Brand Guard ( 1 application 1 class)
✓
Appointment of Lawyer
✓
Objection
✓
Hearing
✓
Infringement support (1)
✓
Power of Attorney (POA)

Frequently asked questions

Common questions about ACEPAR.

What is the status of trademark application 6865420?
The current status of trademark application 6865420 for ACEPAR is Accepted & Advertised.
What is the trademark class of ACEPAR?
ACEPAR is registered under trademark class 5.
Who is the proprietor of ACEPAR?
The proprietor of ACEPAR is DAKSH PHARMACEUTICALS PVT LTD.
When was trademark application 6865420 filed?
Trademark application 6865420 for ACEPAR was filed on 2025-02-19.